AUTHORS
Robert Schwab, MD, MS, Daniel Brown, PhD2, David Degaramo3, Bryan T Ciccarelli, MD, PhD, MA4, Daniel Rader, MD5, Saar Gill, MD, PhD6, Avery Posey, PhD7
AFFILIATIONS
1 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Background
Clonal hematopoiesis of indeterminate potential (CHIP), particularly driven by TET2 mutations, is associated with excess cardiovascular risk. However, existing murine competitive transplantation models do not fully recapitulate human clonal evolution, immune differentiation, tissue-specific mutant clone persistence, or therapeutic responses. A humanized experimental platform linking defined CHIP mutations to vascular disease is needed to define human-specific mechanisms and enable evaluation of clone-directed therapies. We therefore developed a CRISPR-engineered humanized hyperlipidemic model to determine how human TET2-mutant hematopoiesis alters immune composition, systemic inflammation, and atherosclerosis in vivo.
Methods
CRISPR-engineered NSG-LDLR−/− mice were conditioned with busulfan and transplanted with donor-matched wild-type (WT) or TET2 Q654X-edited human CD34+ hematopoietic stem cells. Following confirmation of engraftment, mice were maintained on a Western diet for approximately 12 months. Human hematopoietic engraftment and lineage composition were quantified longitudinally and at study endpoint in peripheral blood, spleen, and aorta by flow cytometry. TET2 variant allele frequency (VAF) was measured serially in peripheral blood and at endpoint in bone marrow, spleen, and aortic tissue by targeted sequencing. Circulating human inflammatory cytokines were measured at 6 months. Aortic plaque burden was quantified by blinded manual Fiji segmentation of standardized stereomicroscopy images.
Results
Following a Western diet, NSG-LDLR−/− mice developed marked hyperlipidemia, with total and non-HDL cholesterol increasing 3.3- and 6.5-fold compared with WT NSG controls (513 vs 156 mg/dL and 353 vs 54 mg/dL; adjusted q<0.0001). TET2 recipients demonstrated significantly greater human hematopoietic chimerism in peripheral blood at 1, 4, and 6 months (median 3.16% vs 1.83%, P=.042; 1.92% vs 0.29%, P=.017; 2.48% vs 0.11%, P=.032; TET2 n=17, WT n=16), while preserving multilineage hematopoietic reconstitution. TET2-mutant clones expanded progressively over time, with peripheral blood median VAF increasing from 7% at 1 month to 21% at 12 months. At 6 months, median VAF reached 27% in bone marrow and 52% in spleen, demonstrating durable expansion of mutant hematopoietic clones. At study completion, TET2-mutant clones remained detectable in peripheral blood, bone marrow, spleen, and atherosclerotic aortic tissue, demonstrating persistent tissue-level clonal representation (median VAF 21%, 18%, 18%, and 19%, respectively).
Although TET2 recipients exhibited greater peripheral blood chimerism early after transplantation, terminal total human chimerism in spleen and aorta was comparable between groups. Despite convergence of terminal human chimerism, TET2 recipients demonstrated increased peripheral blood human myeloid cells at 6 months (1.97% vs 0.82% of human CD45+ cells; P=.040). Circulating human IL-6 increased approximately ninefold (Welch P=.0048; Benjamini-Hochberg q=.048), accompanied by concordant upward trends in IL-1β, IL-2, TNF-α, and IFN-γ. Following approximately 1 year of Western diet, TET2 recipients developed a 5.1-fold greater aortic plaque burden than WT recipients (31.4% vs 6.1%; exact Mann-Whitney P=.0286; n=4/group), with complete separation between groups. Despite comparable terminal human chimerism, plaque burden displayed a strong association with aortic TET2 VAF within TET2 recipients (Pearson r=.953, P=.047; Spearman ρ=1.00, P=.083), implicating mutation-specific biology and local clone burden instead of overall human cell abundance as determinants of vascular disease.
Conclusions
Human TET2-mutant hematopoiesis drives clonal expansion, altered immune composition, systemic inflammatory signaling, and accelerated atherosclerosis despite convergence of terminal human chimerism. Together, these data support a model in which mutation-associated inflammatory biology and local clone burden, rather than overall human engraftment, drive vascular disease. This humanized model provides a translational platform for mechanistic investigation and preclinical evaluation of clone-directed therapies.
DISCLOSURES
Robert Schwab, MD, MS: No relevant conflicts of interest to declare.